Belfi C A, Paul C R, Shan S, Ngo F Q
Dept. Radiology, School of Medicine (BRB-3), Case Western Reserve University, Cleveland, OH 44106.
Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):473-9. doi: 10.1016/0360-3016(94)90441-3.
The differential effects on blood perfusion of the vasodilator hydralazine (HYD) between tumor and normal muscle have been measured using the dynamic enhanced-magnetic resonance imaging (DE-MRI) technique.
DE-MRI is a noninvasive method of determining blood perfusion in tumors and normal tissues using the MR contrast agent Gd-DTPA. Hydralazine is currently being used in an attempt to increase tumor response to bioreductive agents and to hyperthermia.
We show that a dose of 1.2 mg/kg HYD causes an increase in tumor perfusion while doses > or = 2.5 mg/kg cause a decrease in tumor perfusion. The latter was accompanied by a dose-dependent increase in normal muscle perfusion consistent with the "steal effect."
This study demonstrates the sensitivity of the DE-MRI technique and its capability of providing estimates of blood perfusion in normal and tumor tissue as well as in smaller regions of a solid tumor. Such features would make it clinically useful in the study of tumor response to radiation therapy and chemotherapy in patients.
采用动态增强磁共振成像（DE-MRI）技术测量血管扩张剂肼屈嗪（HYD）对肿瘤和正常肌肉血液灌注的不同影响。
DE-MRI是一种使用磁共振造影剂钆-二乙三胺五乙酸（Gd-DTPA）来测定肿瘤和正常组织血液灌注的非侵入性方法。目前正在使用肼屈嗪来尝试提高肿瘤对生物还原药物和热疗的反应。
我们发现，1.2毫克/千克的HYD剂量会导致肿瘤灌注增加，而剂量大于或等于2.5毫克/千克则会导致肿瘤灌注减少。后者伴随着正常肌肉灌注的剂量依赖性增加，这与“盗血效应”一致。
本研究证明了DE-MRI技术的敏感性及其提供正常组织、肿瘤组织以及实体瘤较小区域血液灌注估计值的能力。这些特性将使其在研究患者肿瘤对放射治疗和化疗的反应方面具有临床实用性。
